はじめに
このページでは、OrbiMed Capital GP IV LLCの既知の内部者取引履歴の包括的な分析を提供します。内部者取引を次のチャートに示します。内部者とは、会社の役員、取締役、または重要な投資家のことです。一般的に、内部者が重要な非公開情報に基づいて自社の取引を行うことは一般的に違法です。これは、彼らが自分の会社で取引をすることが違法であるという意味ではありません。ただし、すべての取引をフォーム4を通じてSECに報告しなければなりません。このような制約があるにもかかわらず、学術研究によると、内部者は一般的に、自分の会社の市場を上回るパフォーマンスを発揮する傾向があります。
平均取引収益性
平均取引収益性は、過去3年間に内部者が行ったすべての公開市場での購入の平均収益率です。このリストを生成するために、10b5-1取引計画の一部としてマークされたすべての取引を除いて、内部者が行ったすべての公開市場での計画外の購入を調べます。次に、3、6、および12か月にわたるこれらの取引の平均パフォーマンスを計算し、各期間を平均して、各取引の最終的なパフォーマンス指標を生成します。最後に、内部者のパフォーマンスメトリックを計算するために、すべてのパフォーマンスメトリックを平均します。このリストには、過去2年間に少なくとも3回の取引を行った内部者のみが含まれています。
この内部者取引の収益性が 「N/A」 の場合、インサイダーは過去3年間に公開市場での購入を行っていないか、または行った取引が最近すぎて信頼できるパフォーマンス指標を計算できません。
更新頻度: 1日
内部者ポジションの報告がある企業
SECへの提出書類によると、OrbiMed Capital GP IV LLCは以下の企業の保有または取引を報告しています:
| 証券 | タイトル | 最新の保有報告書 |
|---|---|---|
| US:TELA / TELA Bio, Inc. | 10% Owner | 2,407,242 |
| US:AFIB / Acutus Medical, Inc. | Director, 10% Owner | 1,677,361 |
| US:ALEC / Alector, Inc. | 10% Owner | 1,906,718 |
| 10% Owner | 1,605,713 | |
| US:ARMO / ARMO BioSciences, Inc. | 10% Owner | 409,547 |
| US:BOLD / Boundless Bio, Inc. | 10% Owner | 3,539,997 |
| US:ASNS / Actelis Networks, Inc. | 10% Owner | 0 |
| US:RLYP / Relypsa, Inc. | 10% Owner | 3,356,400 |
| US:OTIC / Otonomy Inc | Director | 1,850,094 |
| US:ICPT / Intercept Pharmaceuticals Inc | Director | 1,120,609 |
| US:MRTX / Mirati Therapeutics, Inc. | 10% Owner | 1,267,000 |
| US:ANTH / Anthera Pharmaceuticals, Inc. | Director | 7,462,000 |
チャートの見方
次のチャートは、OrbiMed Capital GP IV LLCが行った各公開市場の非計画取引後の証券の株価パフォーマンスを示しています。非計画取引とは、10b5-1取引計画の一部として行われなかった取引のことです。株価のパフォーマンスは、株価の累積変化率としてグラフ化されます。たとえば、2019年1月1日に内部者取引が行われた場合、チャートには現在までの証券の日割り変化が表示されます。この間に株価が10ドルから15ドルに上昇した場合、株価の累積変化率は50%となる。価格を10ドルから20ドルに変更すると100%、10ドルから5ドルに変更すると-50%になります。
最終的には、内部者が内部者情報から利益を得るために取引のタイミングを計っているかどうかを確認するために、内部者の取引が株価の超過リターン (プラスまたはマイナス) と、どの程度密接に関連しているかを判断しようとしています。内部者がこれを行っていた状況を考えてみましょう。この状況では、 (a) 購入後のプラスのリターン、または (b) 販売後のマイナスのリターンのいずれかが期待されます。(a) の場合、購入チャートは一連の上向きの曲線を示し、各購入トランザクションの後にプラスのリターンを示します。(b) の場合、販売チャートは一連の下向きの傾斜曲線を示し、各販売取引の後にマイナスのリターンを示します。
しかし、これだけでは結論を導き出すことはできません。例えば、その企業の株価が何年にもわたって非循環的に上昇していた場合、買収後のすべてのプロットは上昇傾向にあると予想されます。同様に、長年にわたる非循環的な下落は、貿易後のプロットを下方に傾斜させます。いずれのチャートもインサイダー取引を示唆するものでありません。
最も強力な指標は、株価が非常に循環的であり、購入チャートにプラスのシグナルがあり、販売チャートにマイナスのプロットがある状況です。この状況は、財務上の利点のために取引のタイミングを計っていた内部者を強く示唆するでしょう。
内部者購入AFIB / Acutus Medical, Inc. - 短期利益分析
このセクションでは、AFIB / Acutus Medical, Inc.で行われたすべての計画外の公開市場内部者購入の収益性を分析します。この分析は、内部者が一貫して異常なリターンを生成しているかどうかを理解するのに役立ちます。この分析は各取引後1年間のものであり、結果は理論的なものです。
次の表は、自動売買プランに含まれていない直近の公開市場買付を示しています。
調整後価格は、分割調整後価格です。調整後株式数は、分割調整後株式数です。
内部者売却AFIB / Acutus Medical, Inc.-短期損失分析
このセクションでは、AFIB / Acutus Medical, Inc.で行われたすべての予定外の公開市場の内部者取引の短期損失回避を分析します。損失回避の一貫したパターンは、将来の売却取引が価格の下落を予測する可能性を示唆しているかもしれません。この分析は各取引後1年間のものであり、結果は理論的なものです。
内部者購入ALEC / Alector, Inc. - 短期利益分析
このセクションでは、AFIB / Acutus Medical, Inc.で行われたすべての計画外の公開市場内部者購入の収益性を分析します。この分析は、内部者が一貫して異常なリターンを生成しているかどうかを理解するのに役立ちます。この分析は各取引後1年間のものであり、結果は理論的なものです。
次の表は、自動売買プランに含まれていない直近の公開市場買付を示しています。
調整後価格は、分割調整後価格です。調整後株式数は、分割調整後株式数です。
内部者売却ALEC / Alector, Inc.-短期損失分析
このセクションでは、AFIB / Acutus Medical, Inc.で行われたすべての予定外の公開市場の内部者取引の短期損失回避を分析します。損失回避の一貫したパターンは、将来の売却取引が価格の下落を予測する可能性を示唆しているかもしれません。この分析は各取引後1年間のものであり、結果は理論的なものです。
次の表は、自動取引プランに含まれていない直近の公開市場での売買を示しています。
調整後価格は、分割調整後価格です。調整後株式数は、分割調整後株式数です。
内部者購入ANTH / Anthera Pharmaceuticals, Inc. - 短期利益分析
このセクションでは、AFIB / Acutus Medical, Inc.で行われたすべての計画外の公開市場内部者購入の収益性を分析します。この分析は、内部者が一貫して異常なリターンを生成しているかどうかを理解するのに役立ちます。この分析は各取引後1年間のものであり、結果は理論的なものです。
次の表は、自動売買プランに含まれていない直近の公開市場買付を示しています。
調整後価格は、分割調整後価格です。調整後株式数は、分割調整後株式数です。
内部者売却ANTH / Anthera Pharmaceuticals, Inc.-短期損失分析
このセクションでは、AFIB / Acutus Medical, Inc.で行われたすべての予定外の公開市場の内部者取引の短期損失回避を分析します。損失回避の一貫したパターンは、将来の売却取引が価格の下落を予測する可能性を示唆しているかもしれません。この分析は各取引後1年間のものであり、結果は理論的なものです。
次の表は、自動取引プランに含まれていない直近の公開市場での売買を示しています。
調整後価格は、分割調整後価格です。調整後株式数は、分割調整後株式数です。
内部者購入BOLD / Boundless Bio, Inc. - 短期利益分析
このセクションでは、AFIB / Acutus Medical, Inc.で行われたすべての計画外の公開市場内部者購入の収益性を分析します。この分析は、内部者が一貫して異常なリターンを生成しているかどうかを理解するのに役立ちます。この分析は各取引後1年間のものであり、結果は理論的なものです。
内部者売却BOLD / Boundless Bio, Inc.-短期損失分析
このセクションでは、AFIB / Acutus Medical, Inc.で行われたすべての予定外の公開市場の内部者取引の短期損失回避を分析します。損失回避の一貫したパターンは、将来の売却取引が価格の下落を予測する可能性を示唆しているかもしれません。この分析は各取引後1年間のものであり、結果は理論的なものです。
次の表は、自動取引プランに含まれていない直近の公開市場での売買を示しています。
調整後価格は、分割調整後価格です。調整後株式数は、分割調整後株式数です。
内部者購入TELA / TELA Bio, Inc. - 短期利益分析
このセクションでは、AFIB / Acutus Medical, Inc.で行われたすべての計画外の公開市場内部者購入の収益性を分析します。この分析は、内部者が一貫して異常なリターンを生成しているかどうかを理解するのに役立ちます。この分析は各取引後1年間のものであり、結果は理論的なものです。
内部者売却TELA / TELA Bio, Inc.-短期損失分析
このセクションでは、AFIB / Acutus Medical, Inc.で行われたすべての予定外の公開市場の内部者取引の短期損失回避を分析します。損失回避の一貫したパターンは、将来の売却取引が価格の下落を予測する可能性を示唆しているかもしれません。この分析は各取引後1年間のものであり、結果は理論的なものです。
次の表は、自動取引プランに含まれていない直近の公開市場での売買を示しています。
調整後価格は、分割調整後価格です。調整後株式数は、分割調整後株式数です。
内部取引の履歴
この表は、証券取引委員会 (SEC) に開示されたOrbiMed Capital GP IV LLCによる内部者取引の完全なリストを示しています。
| 提出日 | 取引日 | フォーム | ティッカー | 証券 | コード | 株式数 | 残り株式数 | 変動 率 |
株式 価格 |
取引 価格 |
残り 価値 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-02 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -36,600 | 2,407,242 | -1.50 | 4.54 | -166,164 | 10,928,879 | |
| 2024-07-02 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -13,700 | 2,443,842 | -0.56 | 4.68 | -64,116 | 11,437,181 | |
| 2024-07-02 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -378,000 | 2,457,542 | -13.33 | 4.74 | -1,791,720 | 11,648,749 | |
| 2023-04-21 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -27,700 | 2,835,542 | -0.97 | 9.41 | -260,657 | 26,682,450 | |
| 2023-04-21 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -28,300 | 2,863,242 | -0.98 | 9.43 | -266,869 | 27,000,372 | |
| 2023-04-21 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -136,000 | 2,891,542 | -4.49 | 9.30 | -1,264,800 | 26,891,341 | |
| 2021-07-21 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 357,143 | 1,677,361 | 27.05 | 14.00 | 5,000,002 | 23,483,054 | |
| 2021-07-21 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 714,285 | 4,872,025 | 17.18 | 14.00 | 9,999,990 | 68,208,350 | |
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -378,733 | 0 | -100.00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -1,202,117 | 0 | -100.00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -389,116 | 0 | -100.00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -899,985 | 0 | -100.00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -647,582 | 0 | -100.00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -673,123 | 0 | -100.00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -872,302 | 0 | -100.00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 1,278,718 | 1,320,218 | 3,081.25 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 3,784,240 | 4,157,740 | 1,013.18 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 41,500 | 41,500 | 18.00 | 747,000 | 747,000 | ||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 373,500 | 373,500 | 18.00 | 6,723,000 | 6,723,000 | ||
| 2020-04-16 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -15,086 | 1,906,718 | -0.78 | 23.53 | -354,974 | 44,865,075 | |
| 2020-04-16 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -47,097 | 5,955,674 | -0.78 | 23.53 | -1,108,192 | 140,137,009 | |
| 2020-04-16 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -5,636 | 1,921,804 | -0.29 | 23.52 | -132,559 | 45,200,830 | |
| 2020-04-16 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -17,595 | 6,002,771 | -0.29 | 23.52 | -413,834 | 141,185,174 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -69,893 | 1,927,440 | -3.50 | 23.79 | -1,662,754 | 45,853,798 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -218,208 | 6,020,366 | -3.50 | 23.79 | -5,191,168 | 143,224,507 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -20,041 | 1,997,333 | -0.99 | 23.65 | -473,970 | 47,236,925 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -62,573 | 6,238,574 | -0.99 | 23.65 | -1,479,851 | 147,542,275 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -2,224 | 2,017,374 | -0.11 | 23.10 | -51,374 | 46,601,339 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -6,946 | 6,301,147 | -0.11 | 23.10 | -160,453 | 145,556,496 | |
| 2020-04-02 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -60,645 | 2,019,598 | -2.92 | 24.50 | -1,485,802 | 49,480,151 | |
| 2020-04-02 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -189,355 | 6,308,093 | -2.91 | 24.50 | -4,639,198 | 154,548,278 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -13,684 | 2,080,243 | -0.65 | 24.66 | -337,447 | 51,298,792 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -42,727 | 6,497,448 | -0.65 | 24.66 | -1,053,648 | 160,227,068 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -16,409 | 2,093,927 | -0.78 | 24.45 | -401,200 | 51,196,515 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -51,235 | 6,540,175 | -0.78 | 24.45 | -1,252,696 | 159,907,279 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -3,541 | 2,110,336 | -0.17 | 26.05 | -92,243 | 54,974,253 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -11,057 | 6,591,410 | -0.17 | 26.05 | -288,035 | 171,706,230 | |
| 2020-03-04 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -38,808 | 0 | -100.00 | 26.00 | -1,009,008 | ||
| 2020-03-04 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -445,086 | 2,113,877 | -17.39 | 26.00 | -11,572,236 | 54,960,802 | |
| 2020-03-04 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -1,390,309 | 6,602,467 | -17.39 | 26.00 | -36,148,034 | 171,664,142 | |
| 2020-01-13 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -1,392 | 38,808 | -3.46 | 19.50 | -27,144 | 756,756 | |
| 2020-01-13 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -91,818 | 2,558,963 | -3.46 | 19.50 | -1,790,451 | 49,899,778 | |
| 2020-01-13 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -286,787 | 7,992,776 | -3.46 | 19.50 | -5,592,346 | 155,859,132 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -1,200 | 40,200 | -2.90 | 18.60 | -22,320 | 747,720 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -2,325 | 2,650,781 | -0.09 | 18.60 | -43,245 | 49,304,527 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -7,275 | 8,279,563 | -0.09 | 18.60 | -135,315 | 153,999,872 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -8,000 | 41,400 | -16.19 | 19.59 | -156,720 | 811,026 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -15,476 | 2,653,106 | -0.58 | 19.59 | -303,175 | 51,974,347 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -48,324 | 8,286,838 | -0.58 | 19.59 | -946,667 | 162,339,156 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -10,400 | 49,400 | -17.39 | 19.82 | -206,128 | 979,108 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -20,350 | 2,668,582 | -0.76 | 19.82 | -403,337 | 52,891,295 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -63,535 | 8,335,162 | -0.76 | 19.82 | -1,259,264 | 165,202,911 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -37,900 | 59,800 | -38.79 | 19.66 | -745,114 | 1,175,668 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -73,879 | 2,688,932 | -2.67 | 19.66 | -1,452,461 | 52,864,403 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -230,721 | 8,398,697 | -2.67 | 19.66 | -4,535,975 | 165,118,383 | |
| 2019-12-19 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -105,500 | 97,700 | -51.92 | 18.52 | -1,953,860 | 1,809,404 | |
| 2019-12-19 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -205,793 | 2,762,811 | -6.93 | 18.52 | -3,811,286 | 51,167,260 | |
| 2019-12-19 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -642,807 | 8,629,418 | -6.93 | 18.52 | -11,904,786 | 159,816,821 | |
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Warrant (right to buy) |
C - Conversion | 758,623 | 758,623 | |||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Warrant (right to buy) |
C - Conversion | -758,623 | 0 | -100.00 | ||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Series B Preferred Stock |
C - Conversion | -24,142,419 | 0 | -100.00 | ||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Series A Preferred Stock |
C - Conversion | -11,878,249 | 0 | -100.00 | ||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
C - Conversion | 977,820 | 3,027,542 | 47.71 | ||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
C - Conversion | 481,095 | 2,049,722 | 30.67 | ||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
P - Purchase | 384,615 | 1,568,627 | 32.48 | 13.00 | 4,999,995 | 20,392,151 | |
| 2019-08-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -157,636 | 2,968,604 | -5.04 | 17.90 | -2,821,684 | 53,138,012 | |
| 2019-08-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -492,364 | 9,272,225 | -5.04 | 17.90 | -8,813,316 | 165,972,828 | |
| 2019-05-22 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
S - Sale | -1,000,000 | 1,605,713 | -38.38 | 30.25 | -30,250,000 | 48,572,818 | |
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series E Preferred Stock |
C - Conversion | -85,295 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series E Preferred Stock |
C - Conversion | -266,437 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series D Preferred Stock |
C - Conversion | -234,601 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series D Preferred Stock |
C - Conversion | -1,012,282 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series C Preferred Stock |
C - Conversion | -528,510 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series C Preferred Stock |
C - Conversion | -2,280,479 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series B Preferred Stock |
C - Conversion | -470,374 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series B Preferred Stock |
C - Conversion | -2,029,626 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series A-2 Preferred Stock |
C - Conversion | -992,437 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series A-2 Preferred Stock |
C - Conversion | -4,282,288 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series A-1 Preferred Stock |
C - Conversion | -94,075 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series A-1 Preferred Stock |
C - Conversion | -405,925 | 0 | -100.00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
P - Purchase | 203,200 | 203,200 | 19.00 | 3,860,800 | 3,860,800 | ||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
P - Purchase | 50,561 | 2,455,853 | 2.10 | 19.00 | 960,659 | 46,661,207 | |
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 85,295 | 2,405,292 | 3.68 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 234,601 | 2,319,997 | 11.25 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 528,510 | 2,085,396 | 33.95 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 470,374 | 1,556,886 | 43.29 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 992,437 | 1,086,512 | 1,054.94 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 94,075 | 94,075 | |||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
P - Purchase | 157,939 | 10,434,976 | 1.54 | 19.00 | 3,000,841 | 198,264,544 | |
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 266,437 | 10,277,037 | 2.66 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 1,012,282 | 10,010,600 | 11.25 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 2,280,479 | 8,998,318 | 33.95 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 2,029,626 | 6,717,839 | 43.29 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 4,282,288 | 4,688,213 | 1,054.95 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 405,925 | 405,925 | |||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Series C Convertible Preferred Stock |
C - Conversion | -167,537 | 0 | -100.00 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Series B-3 Convertible Preferred Stock |
C - Conversion | -544,047 | 0 | -100.00 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Series B-2 Convertible Preferred Stock |
C - Conversion | -260,617 | 0 | -100.00 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -312,741 | 0 | -100.00 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1,070,771 | 0 | -100.00 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
P - Purchase | 250,000 | 2,605,713 | 10.61 | 17.00 | 4,250,000 | 44,297,121 | |
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
C - Conversion | 167,537 | 2,355,713 | 7.66 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
C - Conversion | 544,047 | 2,188,176 | 33.09 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
C - Conversion | 260,617 | 1,644,129 | 18.84 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
C - Conversion | 312,741 | 1,383,512 | 29.21 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
C - Conversion | 1,070,771 | 1,070,771 | |||||
| 2018-06-22 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Common Stock |
U - Other | -409,547 | 409,547 | -50.00 | 50.00 | -20,477,350 | 20,477,350 | |
| 2018-06-22 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Common Stock |
U - Other | -3,709,356 | 3,709,356 | -50.00 | 50.00 | -185,467,800 | 185,467,800 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -16,937 | 3,539,997 | -0.48 | 34.92 | -591,440 | 123,616,695 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -1,066 | 3,556,934 | -0.03 | 36.04 | -38,419 | 128,191,901 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -11,305 | 3,558,000 | -0.32 | 36.44 | -411,954 | 129,653,520 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -47,395 | 3,569,305 | -1.31 | 35.86 | -1,699,585 | 127,995,277 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -21,300 | 3,616,700 | -0.59 | 34.67 | -738,471 | 125,390,989 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -58,428 | 3,638,000 | -1.58 | 34.06 | -1,990,058 | 123,910,280 | |
| 2018-03-06 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -11,372 | 3,696,428 | -0.31 | 33.03 | -375,617 | 122,093,017 | |
| 2018-03-06 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -200 | 3,707,800 | -0.01 | 36.06 | -7,212 | 133,703,268 | |
| 2018-03-06 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -35,558 | 3,708,000 | -0.95 | 36.33 | -1,291,822 | 134,711,640 | |
| 2018-03-06 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -386,080 | 3,743,558 | -9.35 | 35.06 | -13,535,965 | 131,249,143 | |
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series C-1 Convertible Preferred Stock |
C - Conversion | -31,315 | 0 | -100.00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -45,961 | 0 | -100.00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -332,271 | 0 | -100.00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series C-1 Convertible Preferred Stock |
C - Conversion | -283,627 | 0 | -100.00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -415,869 | 0 | -100.00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,226,156 | 0 | -100.00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1,783,704 | 0 | -100.00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Common Stock |
C - Conversion | 409,547 | 409,547 | |||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Common Stock |
C - Conversion | 3,709,356 | 3,709,356 | |||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -2,232,014 | 0 | -100.00 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -229,412 | 0 | -100.00 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -736,648 | 0 | -100.00 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -704,846 | 0 | -100.00 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -66,667 | 0 | -100.00 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 500,000 | 1,868,966 | 36.52 | 10.00 | 5,000,000 | 18,689,660 | |
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 653,974 | 1,368,966 | 91.47 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 114,320 | 714,992 | 19.03 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 328,909 | 600,672 | 121.03 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 252,230 | 271,763 | 1,291.30 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 19,533 | 19,533 | |||||
| 2017-09-29 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -672,000 | 4,129,638 | -14.00 | 28.25 | -18,984,000 | 116,662,274 | |
| 2017-09-11 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Stock Option (right to buy) |
X - Other | -5,000 | 0 | -100.00 | ||||
| 2017-09-11 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -5,000 | 4,801,638 | -0.10 | 22.35 | -111,750 | 107,316,609 | |
| 2017-09-11 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
X - Other | 5,000 | 4,806,638 | 0.10 | 15.03 | 75,150 | 72,243,769 | |
| 2016-07-26 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -343,600 | 3,356,400 | -9.29 | 31.98 | -10,988,328 | 107,337,672 | |
| 2016-07-26 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -3,700,000 | 3,700,000 | -50.00 | 32.00 | -118,400,000 | 118,400,000 | |
| 2016-07-19 | 3 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
448,476 | ||||||||
| 2016-07-19 | 3 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
448,476 | ||||||||
| 2016-07-19 | 3 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
448,476 | ||||||||
| 2016-07-19 | 3 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
448,476 | ||||||||
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -52,058 | 7,400,000 | -0.70 | 27.54 | -1,433,677 | 203,796,000 | |
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -47,942 | 7,452,058 | -0.64 | 26.78 | -1,283,887 | 199,566,113 | |
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -38,630 | 7,500,000 | -0.51 | 27.02 | -1,043,783 | 202,650,000 | |
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -111,370 | 7,538,630 | -1.46 | 26.39 | -2,939,054 | 198,944,446 | |
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -14,171 | 7,650,000 | -0.18 | 28.39 | -402,315 | 217,183,500 | |
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -235,829 | 7,664,171 | -2.99 | 27.50 | -6,485,298 | 210,764,702 | |
| 2015-11-30 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -590 | 1,850,094 | -0.03 | 29.22 | -17,240 | 54,059,747 | |
| 2015-11-30 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -2,716 | 1,850,684 | -0.15 | 28.64 | -77,786 | 53,003,590 | |
| 2015-11-30 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -29,000 | 1,853,400 | -1.54 | 28.97 | -840,130 | 53,692,998 | |
| 2015-11-30 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -34,800 | 1,882,400 | -1.82 | 28.91 | -1,006,068 | 54,420,184 | |
| 2015-11-24 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -36,100 | 1,917,200 | -1.85 | 28.75 | -1,037,875 | 55,119,500 | |
| 2015-11-24 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -80,800 | 1,953,300 | -3.97 | 28.45 | -2,298,760 | 55,571,385 | |
| 2015-11-24 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -83,900 | 2,034,100 | -3.96 | 28.59 | -2,398,701 | 58,154,919 | |
| 2015-11-19 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -127,300 | 2,118,000 | -5.67 | 28.60 | -3,640,780 | 60,574,800 | |
| 2015-11-19 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -200 | 2,245,300 | -0.01 | 29.09 | -5,818 | 65,315,777 | |
| 2015-11-19 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -10,898 | 2,245,500 | -0.48 | 28.80 | -313,862 | 64,670,400 | |
| 2015-10-22 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
P - Purchase | 310,700 | 7,900,000 | 4.09 | 12.92 | 4,014,244 | 102,068,000 | |
| 2015-10-22 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
P - Purchase | 189,300 | 7,589,300 | 2.56 | 11.97 | 2,265,921 | 90,843,921 | |
| 2015-07-21 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
A - Award | 285 | 1,120,609 | 0.03 | ||||
| 2015-05-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -1,457,551 | 7,400,000 | -16.46 | 34.13 | -49,746,216 | 252,562,000 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -90 | 1,120,324 | -0.01 | 294.82 | -26,534 | 330,293,922 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -2,500 | 1,120,414 | -0.22 | 293.85 | -734,625 | 329,233,654 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -6,000 | 1,122,914 | -0.53 | 292.13 | -1,752,780 | 328,036,867 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3,700 | 1,128,914 | -0.33 | 291.12 | -1,077,144 | 328,649,444 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -13,974 | 1,132,614 | -1.22 | 290.02 | -4,052,739 | 328,480,712 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -15,131 | 1,146,588 | -1.30 | 289.07 | -4,373,918 | 331,444,193 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -26,028 | 1,161,719 | -2.19 | 288.11 | -7,498,927 | 334,702,861 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -18,041 | 1,187,747 | -1.50 | 287.16 | -5,180,654 | 341,073,429 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -7,611 | 1,205,788 | -0.63 | 286.24 | -2,178,573 | 345,144,757 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -23,903 | 1,213,399 | -1.93 | 285.18 | -6,816,658 | 346,037,127 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -16,845 | 1,237,302 | -1.34 | 284.20 | -4,787,349 | 351,641,228 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -9,357 | 1,254,147 | -0.74 | 282.87 | -2,646,815 | 354,760,562 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -8,397 | 1,263,504 | -0.66 | 282.13 | -2,369,046 | 356,472,384 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -5,623 | 1,271,901 | -0.44 | 281.11 | -1,580,682 | 357,544,090 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -2,800 | 1,277,524 | -0.22 | 270.23 | -756,644 | 345,225,311 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3,844 | 1,280,324 | -0.30 | 275.56 | -1,059,253 | 352,806,081 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -12,066 | 1,284,168 | -0.93 | 275.00 | -3,318,150 | 353,146,200 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -2,700 | 1,296,234 | -0.21 | 273.19 | -737,613 | 354,118,166 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3,050 | 1,298,934 | -0.23 | 272.13 | -829,996 | 353,478,909 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -6,063 | 1,301,984 | -0.46 | 271.15 | -1,643,982 | 353,032,962 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -9,574 | 1,308,047 | -0.73 | 270.13 | -2,586,225 | 353,342,736 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1,539 | 1,317,621 | -0.12 | 269.10 | -414,145 | 354,571,811 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -6,764 | 1,319,160 | -0.51 | 268.13 | -1,813,631 | 353,706,371 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1,000 | 1,325,924 | -0.08 | 288.60 | -288,600 | 382,661,666 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1,400 | 1,326,924 | -0.11 | 286.04 | -400,456 | 379,553,341 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -52 | 1,328,324 | 0.00 | 283.44 | -14,739 | 376,500,155 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1,548 | 1,328,376 | -0.12 | 283.29 | -438,533 | 376,315,637 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3,500 | 1,329,924 | -0.26 | 282.00 | -987,000 | 375,038,568 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -6,306 | 1,333,424 | -0.47 | 281.01 | -1,772,049 | 374,705,478 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -9,465 | 1,339,730 | -0.70 | 280.00 | -2,650,200 | 375,124,400 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3,668 | 1,349,195 | -0.27 | 279.00 | -1,023,372 | 376,425,405 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -14,152 | 1,352,863 | -1.04 | 278.00 | -3,934,256 | 376,095,914 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -8,195 | 1,367,015 | -0.60 | 276.96 | -2,269,687 | 378,608,474 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -37,666 | 1,375,210 | -2.67 | 275.95 | -10,393,933 | 379,489,200 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3,579 | 1,412,876 | -0.25 | 274.86 | -983,724 | 388,343,097 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -11,869 | 1,416,455 | -0.83 | 273.89 | -3,250,800 | 387,952,860 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -8,638 | 1,428,324 | -0.60 | 272.79 | -2,356,360 | 389,632,504 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -7,764 | 1,436,962 | -0.54 | 271.70 | -2,109,479 | 390,422,575 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -40,598 | 1,444,726 | -2.73 | 270.70 | -10,989,879 | 391,087,328 | |
| 2015-02-05 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 100,000 | 1,267,000 | 8.57 | 20.00 | 2,000,000 | 25,340,000 | |
| 2014-09-18 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -49,000 | 8,857,551 | -0.55 | 25.07 | -1,228,430 | 222,058,804 | |
| 2014-09-18 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -2,600 | 8,906,551 | -0.03 | 26.06 | -67,756 | 232,104,719 | |
| 2014-09-18 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -42,400 | 8,909,151 | -0.47 | 25.45 | -1,079,080 | 226,737,893 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -400 | 1,485,324 | -0.03 | 302.34 | -120,936 | 449,072,858 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -5,400 | 1,485,724 | -0.36 | 301.36 | -1,627,344 | 447,737,785 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -45,058 | 1,491,124 | -2.93 | 300.11 | -13,522,356 | 447,501,224 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -10,400 | 1,536,182 | -0.67 | 299.13 | -3,110,952 | 459,518,122 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1,990 | 1,546,582 | -0.13 | 297.26 | -591,547 | 459,736,965 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -10,010 | 1,548,572 | -0.64 | 296.59 | -2,968,866 | 459,290,969 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -25,442 | 1,558,582 | -1.61 | 295.52 | -7,518,620 | 460,592,153 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -12,558 | 1,584,024 | -0.79 | 294.67 | -3,700,466 | 466,764,352 | |
| 2014-08-19 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
C - Conversion | -378,039 | 0 | -100.00 | ||||
| 2014-08-19 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -1,706,484 | 0 | -100.00 | ||||
| 2014-08-19 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
P - Purchase | 171,875 | 2,256,398 | 8.25 | 16.00 | 2,750,000 | 36,102,368 | |
| 2014-08-19 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 2,084,523 | 2,084,523 | |||||
| 2014-08-19 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -990,000 | 8,951,551 | -9.96 | 26.35 | -26,086,500 | 235,873,369 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -350 | 1,596,582 | -0.02 | 308.13 | -107,844 | 491,948,425 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -14,640 | 1,596,932 | -0.91 | 307.06 | -4,495,314 | 490,349,149 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -525 | 1,611,572 | -0.03 | 306.23 | -160,772 | 493,516,528 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1,732 | 1,612,097 | -0.11 | 305.14 | -528,501 | 491,913,666 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1,193 | 1,613,829 | -0.07 | 303.77 | -362,394 | 490,227,994 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1,100 | 1,615,022 | -0.07 | 302.55 | -332,806 | 488,626,521 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1,710 | 1,616,122 | -0.11 | 301.42 | -515,426 | 487,129,877 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3,985 | 1,617,832 | -0.25 | 300.21 | -1,196,329 | 485,686,109 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -100 | 1,621,817 | -0.01 | 298.61 | -29,861 | 484,290,774 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -9,985 | 1,621,917 | -0.61 | 297.76 | -2,973,134 | 482,942,006 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -6,192 | 1,631,902 | -0.38 | 296.86 | -1,838,139 | 484,441,532 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -7,062 | 1,638,094 | -0.43 | 296.21 | -2,091,814 | 485,214,909 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3,254 | 1,645,156 | -0.20 | 294.96 | -959,800 | 485,255,214 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -4,468 | 1,648,410 | -0.27 | 293.85 | -1,312,908 | 484,380,333 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3,704 | 1,652,878 | -0.22 | 292.70 | -1,084,165 | 483,799,043 | |
| 2014-08-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -324 | 0 | -100.00 | ||||
| 2014-08-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 324 | 1,656,582 | 0.02 | ||||
| 2014-07-01 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -5,000 | 1,167,000 | -0.43 | 20.04 | -100,200 | 23,386,680 | |
| 2014-07-01 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -4,717 | 1,172,000 | -0.40 | 21.11 | -99,576 | 24,740,920 | |
| 2014-07-01 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -9,283 | 1,176,717 | -0.78 | 20.33 | -188,723 | 23,922,657 | |
| 2014-07-01 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -9,212 | 1,186,000 | -0.77 | 23.09 | -212,705 | 27,384,740 | |
| 2014-07-01 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -79,120 | 1,195,212 | -6.21 | 21.79 | -1,724,025 | 26,043,669 | |
| 2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 325 | 1,656,258 | 0.02 | ||||
| 2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 1,330 | 1,655,933 | 0.08 | ||||
| 2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -325 | 324 | -50.08 | ||||
| 2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -1,330 | 0 | -100.00 | ||||
| 2014-04-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -81,305 | 1,654,603 | -4.68 | 320.00 | -26,017,600 | 529,472,960 | |
| 2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -324 | 649 | -33.30 | ||||
| 2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 324 | 1,735,908 | 0.02 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Common Stock |
M - Exercise | -327,133 | 0 | -100.00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Common Stock |
J - Other | 327,133 | 327,133 | |||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Preferred Stock |
J - Other | -327,133 | 0 | -100.00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Common Stock |
M - Exercise | -1,417,578 | 0 | -100.00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Common Stock |
J - Other | 1,417,578 | 1,417,578 | |||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Preferred Stock |
J - Other | -1,417,578 | 0 | -100.00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Series C-2 Preferred Stock |
C - Conversion | -693,991 | 0 | -100.00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Series C-1 Preferred Stock |
C - Conversion | -3,007,297 | 0 | -100.00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Series B-2 Preferred Stock |
C - Conversion | -1,905,702 | 0 | -100.00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Series B-1 Preferred Stock |
C - Conversion | -1,295,845 | 0 | -100.00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
P - Purchase | 712,192 | 9,941,551 | 7.72 | 11.00 | 7,834,112 | 109,357,061 | |
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
F - Taxes | -5,116 | 9,229,359 | -0.06 | 11.00 | -56,276 | 101,522,949 | |
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 327,133 | 9,234,475 | 3.67 | 0.17 | 55,613 | 1,569,861 | |
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
F - Taxes | -22,166 | 8,907,342 | -0.25 | 11.00 | -243,826 | 97,980,762 | |
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 1,417,578 | 8,929,508 | 18.87 | 0.17 | 240,988 | 1,518,016 | |
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
C - Conversion | 693,991 | 7,511,930 | 10.18 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
C - Conversion | 3,007,297 | 6,817,939 | 78.92 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
C - Conversion | 1,905,702 | 3,810,642 | 100.04 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
C - Conversion | 1,904,940 | 1,904,940 | |||||
| 2013-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -325 | 973 | -25.04 | ||||
| 2013-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 325 | 1,735,584 | 0.02 | ||||
| 2013-10-31 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 125,000 | 1,274,332 | 10.88 | 17.50 | 2,187,500 | 22,300,810 | |
| 2013-10-23 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -40,088 | 1,735,259 | -2.26 | 62.50 | -2,505,500 | 108,453,688 | |
| 2013-10-17 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -376,585 | 1,775,347 | -17.50 | 62.50 | -23,536,562 | 110,959,188 | |
| 2013-08-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -325 | 1,298 | -20.02 | ||||
| 2013-08-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 325 | 2,151,932 | 0.02 | ||||
| 2013-07-16 | 3 | MRTX |
Mirati Therapeutics, Inc.
Common Stock |
1,149,332 | ||||||||
| 2013-05-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -324 | 1,623 | -16.64 | ||||
| 2013-05-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 324 | 2,151,607 | 0.02 | ||||
| 2013-04-15 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -649 | 1,947 | -25.00 | ||||
| 2013-04-15 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 649 | 2,151,283 | 0.03 | ||||
| 2013-02-01 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
P - Purchase | 5,700,000 | 7,462,000 | 323.50 | 0.66 | 3,762,000 | 4,924,920 | |
| 2013-01-29 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
P - Purchase | 1,762,000 | 1,762,000 | 0.65 | 1,142,481 | 1,142,481 | ||
| 2012-10-16 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -10,500,000 | 0 | -100.00 | ||||
| 2012-10-16 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
P - Purchase | 333,334 | 2,150,634 | 18.34 | 15.00 | 5,000,010 | 32,259,510 | |
| 2012-10-16 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
C - Conversion | 1,817,300 | 1,817,300 | |||||
| 2012-07-03 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
S - Sale | -1,283,300 | 0 | -100.00 | 0.73 | -942,071 | ||
| 2012-03-22 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
S - Sale | -1,306,700 | 1,283,300 | -50.45 | 2.40 | -3,140,131 | 3,083,898 | |
| 2012-03-22 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
S - Sale | -125,000 | 2,590,000 | -4.60 | 2.87 | -358,312 | 7,424,235 | |
| 2012-03-22 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
S - Sale | -116,800 | 2,715,000 | -4.12 | 2.90 | -338,638 | 7,871,600 |
